Apollomics reports 43% ORR in preliminary vebreltinib Phase 2 trial for Met dysregulation tumors.

Apollomics, a late-stage clinical biopharmaceutical company, reported promising preliminary results from their vebreltinib program for treating various tumors with Met dysregulation, including 43% ORR in SPARTA Phase 2 clinical trial for non-CNS MET fusion solid tumors. The company plans to enroll NSCLC patients with MET amplification. With $25.9M cash as of June 30, 2024, they have a cash runway into Q3 2025.